DE69928563D1 - Verabreichung von neurotropischen wirkstoffen in das zentrale nervensystem - Google Patents
Verabreichung von neurotropischen wirkstoffen in das zentrale nervensystemInfo
- Publication number
- DE69928563D1 DE69928563D1 DE69928563T DE69928563T DE69928563D1 DE 69928563 D1 DE69928563 D1 DE 69928563D1 DE 69928563 T DE69928563 T DE 69928563T DE 69928563 T DE69928563 T DE 69928563T DE 69928563 D1 DE69928563 D1 DE 69928563D1
- Authority
- DE
- Germany
- Prior art keywords
- nervous system
- central nervous
- neurotropic
- activities
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20853898A | 1998-12-09 | 1998-12-09 | |
US208538 | 1998-12-09 | ||
PCT/US1999/029334 WO2000033813A1 (en) | 1998-12-09 | 1999-12-09 | Administration of neurotrophic agents to the central nervous system |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69928563D1 true DE69928563D1 (de) | 2005-12-29 |
DE69928563T2 DE69928563T2 (de) | 2006-07-27 |
Family
ID=22774957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69928563T Expired - Fee Related DE69928563T2 (de) | 1998-12-09 | 1999-12-09 | Abgeben von neurotropischen Wirkstoffen an das Zentralnervensystem |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1137401B1 (de) |
JP (1) | JP2002531489A (de) |
AT (1) | ATE310501T1 (de) |
AU (1) | AU2049500A (de) |
DE (1) | DE69928563T2 (de) |
ES (1) | ES2252993T3 (de) |
WO (1) | WO2000033813A1 (de) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003072056A2 (en) * | 2002-02-25 | 2003-09-04 | Chiron Corporation | Intranasal administration of mc4-r agonists |
US6803046B2 (en) * | 2002-08-16 | 2004-10-12 | Bracco International B.V. | Sincalide formulations |
EP1599474B1 (de) | 2003-03-04 | 2013-04-24 | California Institute Of Technology | Heterocyclische oligomere Verbindungen zur DNS-Erkennung |
WO2004105787A1 (en) * | 2003-05-28 | 2004-12-09 | The University Of Kyoto | Methods of using combinations of egf-2 and egf-20 to treat central nervous system disorders |
US20090136505A1 (en) | 2005-02-23 | 2009-05-28 | Johanna Bentz | Intranasal Administration of Active Agents to the Central Nervous System |
CA2598666A1 (en) * | 2005-02-23 | 2006-08-31 | Alza Corporation | Intranasal administration of active agents to the central nervous system |
EP1928484B1 (de) | 2005-08-26 | 2010-02-24 | The Board Of Trustees Of The Leland Stanford Junior University | Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin |
US8283160B2 (en) * | 2007-09-11 | 2012-10-09 | Frey Ii William H | Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system |
JP2011524373A (ja) | 2008-06-13 | 2011-09-01 | ウィスコンシン・アルムナイ・リサーチ・ファウンデーション | インフルエンザウイルスに対する新規抗ウイルスペプチド |
US9198965B2 (en) | 2008-06-13 | 2015-12-01 | Wisconsin Alumni Research Foundation | Peptide adjuvant for influenza vaccination |
CA2756206A1 (en) | 2009-03-27 | 2010-09-30 | Academia Sinica | Methods and compositions for immunization against virus |
US8718754B2 (en) | 2009-05-19 | 2014-05-06 | Eduard N. Lerner | Device and methods for enhanced multi-delivery of biologically active substances into an organism and to prevent local irritation |
US20120189581A1 (en) | 2009-07-24 | 2012-07-26 | Schultz-Cherry Stacey L | Use of toxoplasma and derived compositions to prevent or treat microbial infections |
US8609088B2 (en) | 2011-05-10 | 2013-12-17 | Regents Of The University Of Minnesota | Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases |
WO2012174481A1 (en) | 2011-06-15 | 2012-12-20 | Nerve Access, Inc. | Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders |
US20130280297A1 (en) | 2012-04-11 | 2013-10-24 | Lori Neal | Use of toxoplasma gene products to prevent or treat microbial infections |
KR101481741B1 (ko) * | 2012-05-18 | 2015-01-13 | 전북대학교산학협력단 | Ⅰgf1을 이용한 변형 프리온 단백질에 의해 유도되는 세포자멸사의 억제방법 |
ES2442242B1 (es) * | 2012-08-09 | 2014-11-25 | Biotechnology Institute, I Mas D, S.L. | Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación. |
EP2916831A4 (de) * | 2012-11-09 | 2016-07-13 | 3E Therapeutics Corp | Röntgenkontrastmittelzusammensetzungen und verfahren zur verwendung davon zur behandlung von leiden im zusammenhang mit entzündungen |
CN115120746A (zh) | 2013-05-15 | 2022-09-30 | 明尼苏达大学董事会 | 腺相关病毒介导的基因向中枢神经系统转移 |
KR20180023884A (ko) | 2015-01-07 | 2018-03-07 | 트라이제미나 인코퍼레이티드 | 마그네슘-함유 옥시토신 제제 및 사용 방법 |
WO2016130683A1 (en) * | 2015-02-10 | 2016-08-18 | University Of Washington | Prolonged anti-diabetic effect of fibroblast growth factor 1 (fgf1) |
WO2017085362A1 (en) * | 2015-11-18 | 2017-05-26 | Herantis Pharma Plc | Compositions comprising cdnf or manf for use in the intranasal treatment of central nervous system diseases |
JP7171439B2 (ja) | 2016-04-15 | 2022-11-15 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ムコ多糖症ii型を処置するための遺伝子療法 |
US11819539B2 (en) | 2017-09-22 | 2023-11-21 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating Mucopolysaccharidosis type II |
WO2019241579A1 (en) | 2018-06-13 | 2019-12-19 | Wisconsin Alumni Research Foundation | Toxoplasma gondii vaccine |
WO2020078568A1 (en) | 2018-10-19 | 2020-04-23 | Humabs Biomed Sa | Antibodies and methods for treatment of lyssavirus infection |
JP7211603B2 (ja) * | 2019-06-21 | 2023-01-24 | 学校法人日本大学 | 薬物送達用組成物および医薬組成物 |
WO2022215036A1 (en) | 2021-04-08 | 2022-10-13 | Vaxthera Sas | Coronavirus vaccine comprising a mosaic protein |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991001739A1 (en) * | 1989-08-11 | 1991-02-21 | Hahnemann University | Dopaminergic neurotrophic factor for treatment of parkinson's disease |
DE69031279T2 (de) * | 1989-12-05 | 1998-03-19 | Ramsey Foundation | Neurologische wirkstoffe zur nasalen verabreichung an das gehirn |
CA2174324A1 (en) * | 1993-10-21 | 1995-04-27 | Katsuya Mukae | Pernasal composition and pernasal preparation containing the same |
KR100568436B1 (ko) * | 1996-02-27 | 2007-04-25 | 데이진 가부시키가이샤 | 분말상경비투여조성물 |
-
1999
- 1999-12-09 AT AT99964208T patent/ATE310501T1/de not_active IP Right Cessation
- 1999-12-09 JP JP2000586307A patent/JP2002531489A/ja active Pending
- 1999-12-09 WO PCT/US1999/029334 patent/WO2000033813A1/en active IP Right Grant
- 1999-12-09 AU AU20495/00A patent/AU2049500A/en not_active Abandoned
- 1999-12-09 EP EP99964208A patent/EP1137401B1/de not_active Expired - Lifetime
- 1999-12-09 ES ES99964208T patent/ES2252993T3/es not_active Expired - Lifetime
- 1999-12-09 DE DE69928563T patent/DE69928563T2/de not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1137401B1 (de) | 2005-11-23 |
AU2049500A (en) | 2000-06-26 |
DE69928563T2 (de) | 2006-07-27 |
EP1137401A1 (de) | 2001-10-04 |
JP2002531489A (ja) | 2002-09-24 |
WO2000033813A1 (en) | 2000-06-15 |
ATE310501T1 (de) | 2005-12-15 |
ES2252993T3 (es) | 2006-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69928563D1 (de) | Verabreichung von neurotropischen wirkstoffen in das zentrale nervensystem | |
RS49828B (sr) | Farmaceutski sastavi | |
ATE73331T1 (de) | Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus. | |
FI911986A (fi) | Farmaceutiska foereningar. | |
DK0751939T3 (da) | Naphthylamider som centralnervesystemmidler | |
PT1066036E (pt) | Agentes com actividade relacionada com serotonina para o tratamento da apneia do sono | |
DE60037578D1 (de) | Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen | |
ATE142877T1 (de) | Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie | |
ATE399553T1 (de) | Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen | |
ID26956A (id) | Pencegahan raf kinase menggunakan simetris dan nonsimetris yang digantikan diphenil urea | |
AU2173400A (en) | Method for administering agents to the central nervous system | |
DK0637306T3 (da) | 4-Imidomethyl-1-[2'-phenyl-2'-oxoethyl]-piperidiner som serotonin-5HT2-antagonister, deres fremstilling og anvendelse til terapi | |
UY26426A1 (es) | Nuevos compuestos | |
HUP0002836A2 (hu) | Makrociklusos bisz(3,3'-indolil)-maleinimid-származékok alkalmazása bőrrendellenességek kezelésére szolgáló gyógyszerkészítmények előállítására | |
BR0112131A (pt) | Composições farmacêuticas e métodos para uso | |
HUP0100611A2 (hu) | Triazin vegyületek, és ilyeneket tartalmazó gyógyszerkészítmények a központi idegrendszer elváltozásainak kezelésére | |
DK0871446T3 (da) | Anvendelse af eliprodil til fremstilling af et lægemiddel til behandling af ischaemiske sygdomme i nethinden eller den optiske nerve | |
TR199901385T2 (xx) | Piperidin t�revleri. | |
HUP9701606A2 (hu) | Szulbutiamin alkalmazása bizonyos pszichomotoros és pszichointellektuális rendellenességek kezelésére használható gyógyszerkészítmények előállítására | |
GR1003591B (el) | Μεσον για την αυξηση της απελευθερωσης ακετυλχολινης στον εγκεφαλο. | |
DE69530600D1 (de) | Verwendung von nk1-rezeptor antagonisten zur zubereitung von arzneimitteln mit kardioregulierender wirkung | |
TR200000916T2 (tr) | İkameli piperidin türevleri. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US |
|
8339 | Ceased/non-payment of the annual fee |